世界のナノ医療市場2021年ｰ2028年：用途別（心臓血管、抗炎症、抗感染症、神経、腫瘍、その他[歯科、整形外科、泌尿器科、眼科）

• 英文タイトル：Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

• レポートコード：MRC2205A017 • 出版社/出版日：Transparency Market Research / 2022年3月21日 • レポート形態：英文、PDF、273ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の本調査レポートは、世界のナノ医療市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、用途別（心臓血管、抗炎症、抗感染症、神経、腫瘍）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のナノ医療市場規模：用途別（心臓血管、抗炎症、抗感染症、神経、腫瘍） ・世界のナノ医療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況

Nanomedicine Market – Scope of Report

TMR’s report on the global nanomedicine market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global nanomedicine market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global nanomedicine market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global nanomedicine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global nanomedicine market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global nanomedicine market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global nanomedicine market.

The report delves into the competitive landscape of the global nanomedicine market. Key players operating in the global nanomedicine market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global nanomedicine market that have been profiled in this report.

Key Questions Answered in Nanomedicine Market Report
What is the scope of growth of product companies in the global nanomedicine market?
What will be the Y-o-Y growth of the global nanomedicine market between 2017 and 2028?
What is the influence of changing trends in technologies on the global nanomedicine market?
Will North America be the most profitable market for nanomedicine providers?
Which factors are anticipated to hamper the growth of the global nanomedicine market during the forecast period?
Which are the leading companies in the global nanomedicine market?

Research Methodology
TMR has utilized a unique research methodology to conduct comprehensive research on the growth of the global nanomedicine market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global nanomedicine market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the nanomedicine market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the nanomedicine market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global nanomedicine market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global nanomedicine market more reliably and accurately.

レポート目次

---

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nanomedicine Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nanomedicine Market Analysis and Forecast, 2017–2028
5. Key Insights
5.1. Technological Advancements
5.2. Key Mergers & Acquisitions
5.3. Regulatory Scenario by Region/globally
5.4. COVID-19 Pandemics Impact on Industry
6. Global Nanomedicine Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017–2028
6.3.1. Cardiovascular
6.3.2. Anti-inflammatories
6.3.3. Anti-invectives
6.3.4. Neurology
6.3.5. Oncology
6.3.6. Others
6.4. Market Attractiveness Analysis, by Application
7. Global Nanomedicine Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Nanomedicine Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Application, 2017–2028
8.2.1. Cardiovascular
8.2.2. Anti-inflammatories
8.2.3. Anti-infective
8.2.4. Neurology
8.2.5. Oncology
8.2.6. Others
8.3. Market Value Forecast, by Country, 2017–2028
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Application
8.4.2. By Country
9. Europe Nanomedicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Application, 2017–2028
9.2.1. Cardiovascular
9.2.2. Anti-inflammatories
9.2.3. Cardiovascular
9.2.4. Neurology
9.2.5. Oncology
9.2.6. Others
9.3. Market Value Forecast, by Country/Sub-region, 2017–2028
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Application
9.4.2. By Country/Sub-region
10. Asia Pacific Nanomedicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Application, 2017–2028
10.2.1. Cardiovascular
10.2.2. Anti-inflammatories
10.2.3. Anti-infective
10.2.4. Neurology
10.2.5. Oncology
10.2.6. Others
10.3. Market Value Forecast, by Country/Sub-region, 2017–2028
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Application
10.4.2. By Country/Sub-region
11. Latin America Nanomedicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Application, 2017–2028
11.2.1. Cardiovascular
11.2.2. Anti-inflammatories
11.2.3. Anti-infectives
11.2.4. Neurology
11.2.5. Oncology
11.2.6. Others
11.3. Market Value Forecast, by Country/Sub-region, 2017–2028
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Application
11.4.2. By Country/Sub-region
12. Middle East & Africa Nanomedicine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Application, 2017–2028
12.2.1. Cardiovascular
12.2.2. Anti-inflammatories
12.2.3. Anti-infectives
12.2.4. Neurology
12.2.5. Oncology
12.2.6. Others
12.3. Market Value Forecast, by Country/Sub-region, 2017–2028
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Application
12.4.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player – Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis, by Company, 2020
13.3. Company Profiles
13.3.1. Abbott Laboratories
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Financial Analysis
13.3.1.3. Growth Strategies
13.3.1.4. SWOT Analysis
13.3.2. CombiMatrix Corporation
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Financial Analysis
13.3.2.3. Growth Strategies
13.3.2.4. SWOT Analysis
13.3.3. Celgene Corporation
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Financial Analysis
13.3.3.3. Growth Strategies
13.3.3.4. SWOT Analysis
13.3.4. GE Healthcare
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Financial Analysis
13.3.4.3. Growth Strategies
13.3.4.4. SWOT Analysis
13.3.5. Johnson & Johnson
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Financial Analysis
13.3.5.3. Growth Strategies
13.3.5.4. SWOT Analysis
13.3.6. Mallinckrodt plc
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Financial Analysis
13.3.6.3. Growth Strategies
13.3.6.4. SWOT Analysis
13.3.7. Merck & Company Inc.
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Financial Analysis
13.3.7.3. Growth Strategies
13.3.7.4. SWOT Analysis
13.3.8. Nanosphere, Inc.
13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.8.2. Financial Analysis
13.3.8.3. Growth Strategies
13.3.8.4. SWOT Analysis
13.3.9. Pfizer Inc.
13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.9.2. Financial Analysis
13.3.9.3. Growth Strategies
13.3.9.4. SWOT Analysis
13.3.10. Sigma-Tau Pharmaceuticals Inc.
13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.10.2. Financial Analysis
13.3.10.3. Growth Strategies
13.3.10.4. SWOT Analysis
13.3.11. Teva Pharmaceutical Industries Ltd
13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.11.2. Financial Analysis
13.3.11.3. Growth Strategies
13.3.11.4. SWOT Analysis
13.3.12. UCB S.A.
13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.12.2. Financial Analysis
13.3.12.3. Growth Strategies
13.3.12.4. SWOT Analysis

---